Bio-Techne Corp (TECH) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

21/25

Growth 5 Margin 3 Expansion 5 Platform 3 Financial 5

latest quarter score

Earnings Reports

21
Biotechni (TECH) Q2 2026: Cell Therapy Headwinds Drive 30% GMP Reagent Volatility, Margin Expansion Holds
June 15, 2026
22
Bio-Techne (TECH) Q3 2026: Comet Platform Backlog Up 65% as Spatial Biology Momentum Builds
May 06, 2026
19
Bio-Techne (TECH) Q1 2026: Cell Therapy Headwind Drives 400 bps Growth Drag, Margin Expansion Outpaces Peers
November 05, 2025
17
Biotechne (TECH) Q4 2025: Exosome Divestiture Drives 100bps Margin Expansion Amid Funding Uncertainty
August 06, 2025
20
Biotechne (TECH) Q3 2025: Tariff Exposure Capped at $20M as Margin Discipline Holds Amid NIH Uncertainty
July 07, 2025

Browse all companies